Who
J. Martin Carroll
Director
Company insider
Files Form 4 as: Director, Esperion Therapeutics; Director, Catalent; Director, TherapeuticsMD; Director, Mallinckrodt; Director, Rocket Pharmaceuticals; Director, Durata Therapeutics; Director, Vivus.
In numbers
- Trades disclosed
- 96
- Buys
- 8
- Sells
- 1
- Bought
- $572K
- Sold
- $17K
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 9 May 2013
- Last trade
- 13 Jul 2026
- Last filed
- 13 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Jul 2026filed 13 Jul 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code D | —177,523 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —21,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,500 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —21,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —32,500 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —44,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeutics | SEC FORM 4 Code D | —177,523 | filing |
| 28 May 2026filed 1 Jun 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code A | —79,873 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | Esperion Therapeutics | SEC FORM 4 Code A | —79,873 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | Esperion Therapeutics | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
| 18 Dec 2024filed 18 Dec 2024 | Catalent | SEC FORM 4 Code D | —32,734 | filing |
| 30 Oct 2024filed 1 Nov 2024 | Catalent | SEC FORM 4 Code A | —4,663 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | Esperion Therapeutics | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 27 Oct 2023filed 31 Oct 2023 | Catalent | SEC FORM 4 Code A | —6,993 at $0.00 | filing |
| 1 Jul 2023filed 7 Jul 2023 | Catalent | SEC FORM 4 Code A | —555 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | Esperion Therapeutics | SEC FORM 4 Code A | —5,150 at $0.00 | filing |
News
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Crosses Below Fifty Day Moving Average – Should You Sell?RCKT · dailypolitical.com · 22 Oct 2026TherapeuticsMD (NASDAQ:TXMD) vs. Addex Therapeutics (NASDAQ:ADXN) Head to Head ComparisonTXMD · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name J. Martin Carroll; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.